Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 for lower limb spasticity due to stroke or traumatic brain injury
2018-001639-35Phase 3Active
- Sponsor
- Merz
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in stroke, spastic paresis and lower extremity spasticity comparing NT 201 400 U with Placebo (2 arms). Primary endpoint: Co-primary efficacy variables. Started Apr 2019; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
strokespastic paresislower extremity spasticity
Beyond the preview
Go deeper on 2018-001639-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001639-35.